Clinical Trial Update: A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 study evaluating teclistamab in combination with daratumumab subcutaneously versus DPd or DVd regimens in relapsed or refractory multiple myeloma; the t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT))
• Decadron (Dexamethasone)
• Pomalyst (pomalidomide)
• TECVAYLI (TECLISTAMAB-CQYV)
• Velcade (bortezomib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING